Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cancer Immunotherapy: Mixing, Matching, And Making Nice

This article was originally published in Start Up

Executive Summary

Cancer immunotherapy's potential payoff is big enough that acknowledged competitors are settling disputes, potential competitors are forging alliances, and start-ups like their chances of success. Profiles of Annias Immunotherapeutics, Costanoan Immunotherapies, and Unum Therapeutics.

You may also be interested in...

Annias Immunotherapeutics Inc.

Every would-be developer of cancer immunotherapeutics faces the same basic problem: how to get the body's immune system to destroy cancerous cells without harming healthy ones. The founders of Annias Immunotherapeutics Inc. think they have found a way to help the body push through immune tolerance and become better able to seek and destroy solid tumors; the trick is targeting a virus that has recently been discovered to be present in certain types of tumors, but not in surrounding healthy tissue.

Unum Therapeutics Inc.

Unum Therapeutics Inc. is developing a new way of treating cancer that combines components of two different immune-system cells, natural killer cells and T cells. The start-up's therapeutic approach calls for modifying patients' own T cells with a hybrid molecule, called an antibody-coupled T-cell receptor , then co-administering them with antibodies designed to recognize specific proteins on the surface of tumors.

Costanoan Immunotherapies Inc.

Costanoan Immunotherapies Inc. aims to immunize cancer patients with polymer particles, or beads, that display antigens and other immunomodulators in regular patterns. Data in animals show that Costanoan's antigen-bearing beads stimulate an immune response stronger than antigens presented as peptides alone.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts